SRBZF Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 0.96% compared to Stratec SE's net margin of 15.91%. Stratec SE's return on equity of 4.35% beat BioNTech SE's return on equity of -2.35%.

Stratec SE has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $136.02 which suggests that it could grow by 13.15%. Given that BioNTech SE has higher upside potential than Stratec SE, analysts believe BioNTech SE is more attractive than Stratec SE.

Stratec SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.764%.

Stratec SE has a quarterly dividend of $0.60 per share corresponding to a yield of 0.82%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stratec SE pays 90.23% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Stratec SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stratec SE quarterly revenues are $62.9M, which are smaller than BioNTech SE quarterly revenues of $1.4B. Stratec SE's net income of $603.8K is lower than BioNTech SE's net income of $217.9M. Notably, Stratec SE's price-to-earnings ratio is 81.49x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stratec SE is 3.27x versus 8.78x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 0.96% compared to Stratec SE's net margin of 68.44%. Stratec SE's return on equity of 4.35% beat CureVac NV's return on equity of 21.3%.

Stratec SE has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $7.30 which suggests that it could grow by 64.51%. Given that CureVac NV has higher upside potential than Stratec SE, analysts believe CureVac NV is more attractive than Stratec SE.

Stratec SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Stratec SE has a quarterly dividend of $0.60 per share corresponding to a yield of 0.82%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stratec SE pays 90.23% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Stratec SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stratec SE quarterly revenues are $62.9M, which are smaller than CureVac NV quarterly revenues of $543.2M. Stratec SE's net income of $603.8K is lower than CureVac NV's net income of $371.8M. Notably, Stratec SE's price-to-earnings ratio is 81.49x while CureVac NV's PE ratio is 8.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stratec SE is 3.27x versus 1.67x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of 0.96% compared to Stratec SE's net margin of -14092.9%. Stratec SE's return on equity of 4.35% beat InflaRx NV's return on equity of -61.55%.

Stratec SE has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of -- which suggests that it could grow by 251.27%. Given that InflaRx NV has higher upside potential than Stratec SE, analysts believe InflaRx NV is more attractive than Stratec SE.

Stratec SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.659%.

Stratec SE has a quarterly dividend of $0.60 per share corresponding to a yield of 0.82%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stratec SE pays 90.23% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Stratec SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stratec SE quarterly revenues are $62.9M, which are larger than InflaRx NV quarterly revenues of $136.2K. Stratec SE's net income of $603.8K is higher than InflaRx NV's net income of -$19.2M. Notably, Stratec SE's price-to-earnings ratio is 81.49x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stratec SE is 3.27x versus 730.60x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of 0.96% compared to Stratec SE's net margin of -16.95%. Stratec SE's return on equity of 4.35% beat Immatics NV's return on equity of -16.88%.

Stratec SE has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $16.75 which suggests that it could grow by 130.08%. Given that Immatics NV has higher upside potential than Stratec SE, analysts believe Immatics NV is more attractive than Stratec SE.

Stratec SE has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.769%.

Stratec SE has a quarterly dividend of $0.60 per share corresponding to a yield of 0.82%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stratec SE pays 90.23% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Stratec SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stratec SE quarterly revenues are $62.9M, which are larger than Immatics NV quarterly revenues of $55.6M. Stratec SE's net income of $603.8K is higher than Immatics NV's net income of -$9.4M. Notably, Stratec SE's price-to-earnings ratio is 81.49x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stratec SE is 3.27x versus 5.84x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.